140 related articles for article (PubMed ID: 35852888)
21. Turnover among new Medicare Advantage enrollees may be greater than perceived.
Dong J; Zaslavsky AM; Ayanian JZ; Landon BE
Am J Manag Care; 2022 Oct; 28(10):539-542. PubMed ID: 36252173
[TBL] [Abstract][Full Text] [Related]
22. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
[No Abstract] [Full Text] [Related]
23. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
24. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
25. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
[TBL] [Abstract][Full Text] [Related]
26. Prices for Physicians' Services in Medicare Advantage and Commercial Plans.
Pelech DM
Med Care Res Rev; 2020 Jun; 77(3):236-248. PubMed ID: 29936886
[TBL] [Abstract][Full Text] [Related]
27. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
28. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.
Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222
[TBL] [Abstract][Full Text] [Related]
29. Physician Reimbursement in Medicare Advantage Compared With Traditional Medicare and Commercial Health Insurance.
Trish E; Ginsburg P; Gascue L; Joyce G
JAMA Intern Med; 2017 Sep; 177(9):1287-1295. PubMed ID: 28692718
[TBL] [Abstract][Full Text] [Related]
30. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
31. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
Bowman J; Rousseau A; Silk D; Harrison C
Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
[TBL] [Abstract][Full Text] [Related]
32. Coverage and prior authorization of psychotropic drugs under Medicare Part D.
Huskamp HA; Stevenson DG; Donohue JM; Newhouse JP; Keating NL
Psychiatr Serv; 2007 Mar; 58(3):308-10. PubMed ID: 17325102
[TBL] [Abstract][Full Text] [Related]
33. Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans.
Mark TL; Parish W; Zarkin GA
JAMA; 2019 Jul; 322(2):166-167. PubMed ID: 31287514
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical demand response to utilization management.
Sarig O
J Health Econ; 2024 Jan; 93():102830. PubMed ID: 38113754
[TBL] [Abstract][Full Text] [Related]
35. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
36. Trends in Medicare Advantage participation among commercial insurers.
Marr J; Meiselbach MK; Polsky D
Am J Manag Care; 2023 Oct; 29(10):e317-e319. PubMed ID: 37870553
[TBL] [Abstract][Full Text] [Related]
37. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
38. Drug plan design incentives among Medicare prescription drug plans.
Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
[TBL] [Abstract][Full Text] [Related]
39. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
[TBL] [Abstract][Full Text] [Related]
40. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
